%0 Journal Article
%T 免疫检查点在胃癌中的研究进展<br>Research Progress on the Study of Immune Checkpoints in Gastric Cancer
%A 蒲艳霞
%A 王若峥
%J Advances in Clinical Medicine
%P 2144-2150
%@ 2161-8720
%D 2024
%I Hans Publishing
%R 10.12677/acm.2024.1441275
%X 胃癌是全球最常见的消化道肿瘤之一。由于其晚期的患者预后较差，单纯传统的化疗效果并不能满足患者治疗需求，因此挖掘新的治疗策略来改善该疾病的生存率势在必行。目前程序性死亡受体1 (programmed cell death 1, PD-1)抑制剂联合化疗已用于晚期胃癌一线治疗。随着对胃癌免疫基因组学的进一步了解，新的免疫检查点调节剂可能变得更加重要，人们越来越关注在先进的姑息治疗环境中寻找可成药的靶点，发现新的预测生物标志物和实现个性化治疗势在必行。对免疫系统功能的进一步研究和认识将有助于未来免疫治疗的发展。<br />
Gastric cancer is one of the most frequent tumors in the digestive tract. Due to the poor prognosis of patients with its advanced stage, the effect of traditional chemotherapy alone cannot meet the patients’ therapeutic needs, so it is imperative to explore new therapeutic strategies to improve the survival rate of this disease. Currently, programmed cell death 1 (PD-1) inhibitors combined with chemotherapy have been used as the first-line treatment for advanced gastric cancer. With further understanding of the immunogenomics of gastric cancer, new immune checkpoint modulators are likely to become more important, and there is a growing interest in finding druggable targets in the advanced palliative care setting, where the discovery of new predictive biomarkers and the realization of personalized therapy are imperative. Further research and understanding of immune system function will contribute to the future development of immunotherapy.
%K 胃癌，免疫检查点，生物标志物<br>Gastric Cancer
%K Immune Checkpoints
%K Biomarkers
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=85464